ENTA

SVB Securities analyst Roanna Ruiz reiterated a Hold rating on Enanta Pharmaceuticals (ENTA - Research Report) on November 9 and set a price target of $112.00. The company's shares closed last Friday at $45.21.According to TipRanks, Ruiz is an analyst with an average return of -44.1% and a 12.24% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as scPharmaceuticals, Pardes Biosciences, and Amarin.Currently, the analyst consensus on Enanta Pharmaceuticals is a Moderate Buy with an average price target of $90.20.See the top stocks recommended by analysts >>Based on Enanta Pharmaceuticals' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $19.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-their-hold-rating-for-enanta-pharmaceuticals-enta?utm_source=advfn.com&utm_medium=referral